Quarterly ResultNov 6, 2026, 09:06 AM
Immunocore Q3 Net Revenues $102.2M; Net Loss $14.2M; Autoimmune Candidate Dosed
AI Summary
Immunocore Holdings plc reported its third quarter financial results for the period ended September 30, 2026. KIMMTRAK net revenues for Q3 2026 were $102.2 million, a slight decrease year-over-year, but year-to-date net revenues reached $324.8 million, marking a 10% increase. The company also provided a business update, highlighting the completion of enrollment for the Phase 3 TEBE-AM trial and the dosing of the first patient in the IMC-S118AI Phase 1 trial for type 1 diabetes. The company reported a net loss of $14.2 million for the quarter, compared to a net loss of $0.2 million in the prior year period, with R&D expenses increasing to $74.7 million.
Key Highlights
- KIMMTRAK Q3 2026 net revenues were $102.2M, down 1.4% YoY; YTD net revenues $324.8M, up 10% YoY.
- Phase 3 TEBE-AM trial for advanced cutaneous melanoma completed enrollment; topline OS data expected Q2 2027.
- First patient dosed in Phase 1 trial of IMC-S118AI for type 1 diabetes.
- Cash, cash equivalents, and marketable securities stood at $901M as of Sept 30, 2026.
- Q3 2026 net loss was $14.2M ($0.28 loss per share), compared to $0.2M ($0.00 loss per share) in Q3 2025.
- R&D expenses increased to $74.7M in Q3 2026 from $70.6M in Q3 2025.
- Promising Phase 1 data with KIMMTRAK plus brenetafusp to be presented at SITC; Phase 2/3 DUET-UVEAL trial planned.
Price Impact
More from IMCR